ERBB2 and breast cancer: Olaparib (Lynparza®︎) is a molecular-targeted agent indicated for the treatment of “BRCA mutation-positive, HER2-negative inoperable or recurrent BC with prior cancer chemotherapy” and is an inhibitor of poly (ADP-ribose) polymerase, which repairs damaged DNA single strands, leading to the death of cancer cells.